PS6K amplification characterizes a small subset of anaplastic meningiomas

D. X. Cai, C. D. James, B. W. Scheithauer, Fergus J Couch, A. Perry

Research output: Contribution to journalArticle

43 Citations (Scopus)

Abstract

PS6K, a putative oncogene mapped to chromosome 17q23, encodes a serine/threonine kinase, which phosphorylates ribosomal subunit 6 and is part of the insulin receptor signal transduction pathway involved in the regulation of messenger RNA translation, protein synthesis, cell cycle progression, and cell size. Comparative genomic hybridization studies have detected 17q23 amplifications in a subset of meningiomas, particularly those with aggressive histologic features. PS6K amplifications have been reported in breast cancer, another hormonally driven neoplasm. We assessed PS6K dosage in 94 archival paraffin-embedded meningiomas using dual-color fluorescence in situ hybridization. We found high-level PS6K amplifications in 3 of 22 anaplastic grade III meningiomas. Amplification was confirmed by differential polymerase chain reaction in 1 of these cases. In contrast, no amplifications were identified in 37 benign (grade I) and 35 atypical (grade II) meningiomas. To our knowledge, this represents the first report of gene amplification in primary human meningiomas. Given its exclusive association with anaplastic meningiomas, PS6K amplification likely occurs during the malignant progression of a small subset of anaplastic tumors. Further studies are needed to map the 17q23 amplicon to determine whether additional genes in this region are amplified in highgrade meningiomas.

Original languageEnglish (US)
Pages (from-to)213-218
Number of pages6
JournalAmerican Journal of Clinical Pathology
Volume115
Issue number2
DOIs
StatePublished - 2001
Externally publishedYes

Fingerprint

Meningioma
Ribosome Subunits
Cell Cycle Proteins
Comparative Genomic Hybridization
Gene Amplification
Protein-Serine-Threonine Kinases
Insulin Receptor
Fluorescence In Situ Hybridization
Cell Size
Oncogenes
Paraffin
Signal Transduction
Neoplasms
Color
Chromosomes
Breast Neoplasms
Polymerase Chain Reaction
Messenger RNA
Genes

Keywords

  • FISH
  • Fluorescence in situ hybridization
  • Gene amplification
  • Meningioma
  • Prognosis
  • PS6K

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

PS6K amplification characterizes a small subset of anaplastic meningiomas. / Cai, D. X.; James, C. D.; Scheithauer, B. W.; Couch, Fergus J; Perry, A.

In: American Journal of Clinical Pathology, Vol. 115, No. 2, 2001, p. 213-218.

Research output: Contribution to journalArticle

Cai, D. X. ; James, C. D. ; Scheithauer, B. W. ; Couch, Fergus J ; Perry, A. / PS6K amplification characterizes a small subset of anaplastic meningiomas. In: American Journal of Clinical Pathology. 2001 ; Vol. 115, No. 2. pp. 213-218.
@article{cd5837d2babc46ac951016d96c6c4e02,
title = "PS6K amplification characterizes a small subset of anaplastic meningiomas",
abstract = "PS6K, a putative oncogene mapped to chromosome 17q23, encodes a serine/threonine kinase, which phosphorylates ribosomal subunit 6 and is part of the insulin receptor signal transduction pathway involved in the regulation of messenger RNA translation, protein synthesis, cell cycle progression, and cell size. Comparative genomic hybridization studies have detected 17q23 amplifications in a subset of meningiomas, particularly those with aggressive histologic features. PS6K amplifications have been reported in breast cancer, another hormonally driven neoplasm. We assessed PS6K dosage in 94 archival paraffin-embedded meningiomas using dual-color fluorescence in situ hybridization. We found high-level PS6K amplifications in 3 of 22 anaplastic grade III meningiomas. Amplification was confirmed by differential polymerase chain reaction in 1 of these cases. In contrast, no amplifications were identified in 37 benign (grade I) and 35 atypical (grade II) meningiomas. To our knowledge, this represents the first report of gene amplification in primary human meningiomas. Given its exclusive association with anaplastic meningiomas, PS6K amplification likely occurs during the malignant progression of a small subset of anaplastic tumors. Further studies are needed to map the 17q23 amplicon to determine whether additional genes in this region are amplified in highgrade meningiomas.",
keywords = "FISH, Fluorescence in situ hybridization, Gene amplification, Meningioma, Prognosis, PS6K",
author = "Cai, {D. X.} and James, {C. D.} and Scheithauer, {B. W.} and Couch, {Fergus J} and A. Perry",
year = "2001",
doi = "10.1309/FVNU-7UBY-DXE3-77MT",
language = "English (US)",
volume = "115",
pages = "213--218",
journal = "American Journal of Clinical Pathology",
issn = "0002-9173",
publisher = "American Society of Clinical Pathologists",
number = "2",

}

TY - JOUR

T1 - PS6K amplification characterizes a small subset of anaplastic meningiomas

AU - Cai, D. X.

AU - James, C. D.

AU - Scheithauer, B. W.

AU - Couch, Fergus J

AU - Perry, A.

PY - 2001

Y1 - 2001

N2 - PS6K, a putative oncogene mapped to chromosome 17q23, encodes a serine/threonine kinase, which phosphorylates ribosomal subunit 6 and is part of the insulin receptor signal transduction pathway involved in the regulation of messenger RNA translation, protein synthesis, cell cycle progression, and cell size. Comparative genomic hybridization studies have detected 17q23 amplifications in a subset of meningiomas, particularly those with aggressive histologic features. PS6K amplifications have been reported in breast cancer, another hormonally driven neoplasm. We assessed PS6K dosage in 94 archival paraffin-embedded meningiomas using dual-color fluorescence in situ hybridization. We found high-level PS6K amplifications in 3 of 22 anaplastic grade III meningiomas. Amplification was confirmed by differential polymerase chain reaction in 1 of these cases. In contrast, no amplifications were identified in 37 benign (grade I) and 35 atypical (grade II) meningiomas. To our knowledge, this represents the first report of gene amplification in primary human meningiomas. Given its exclusive association with anaplastic meningiomas, PS6K amplification likely occurs during the malignant progression of a small subset of anaplastic tumors. Further studies are needed to map the 17q23 amplicon to determine whether additional genes in this region are amplified in highgrade meningiomas.

AB - PS6K, a putative oncogene mapped to chromosome 17q23, encodes a serine/threonine kinase, which phosphorylates ribosomal subunit 6 and is part of the insulin receptor signal transduction pathway involved in the regulation of messenger RNA translation, protein synthesis, cell cycle progression, and cell size. Comparative genomic hybridization studies have detected 17q23 amplifications in a subset of meningiomas, particularly those with aggressive histologic features. PS6K amplifications have been reported in breast cancer, another hormonally driven neoplasm. We assessed PS6K dosage in 94 archival paraffin-embedded meningiomas using dual-color fluorescence in situ hybridization. We found high-level PS6K amplifications in 3 of 22 anaplastic grade III meningiomas. Amplification was confirmed by differential polymerase chain reaction in 1 of these cases. In contrast, no amplifications were identified in 37 benign (grade I) and 35 atypical (grade II) meningiomas. To our knowledge, this represents the first report of gene amplification in primary human meningiomas. Given its exclusive association with anaplastic meningiomas, PS6K amplification likely occurs during the malignant progression of a small subset of anaplastic tumors. Further studies are needed to map the 17q23 amplicon to determine whether additional genes in this region are amplified in highgrade meningiomas.

KW - FISH

KW - Fluorescence in situ hybridization

KW - Gene amplification

KW - Meningioma

KW - Prognosis

KW - PS6K

UR - http://www.scopus.com/inward/record.url?scp=0035126321&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035126321&partnerID=8YFLogxK

U2 - 10.1309/FVNU-7UBY-DXE3-77MT

DO - 10.1309/FVNU-7UBY-DXE3-77MT

M3 - Article

C2 - 11211609

AN - SCOPUS:0035126321

VL - 115

SP - 213

EP - 218

JO - American Journal of Clinical Pathology

JF - American Journal of Clinical Pathology

SN - 0002-9173

IS - 2

ER -